EC Microbiology

Editorial Volume 19 Issue 3 - 2023

Immunogenicity and Safety of mRNA-COVID-19 Vaccines in Immune-Checkpoint-Inhibitor-Receiving-Lung- Cancer Patients

Attapon Cheepsattayakorn1,2*, Ruangrong Cheepsattayakorn3 and Porntep Siriwanarangsun1

1Faculty of Medicine, Western University, Pathumtani Province, Thailand

210th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand

3Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

*Corresponding Author: Attapon Cheepsattayakorn, 10th Zonal Tuberculosis and Chest Disease Center, Chiang Mai, Thailand.
Received: March 02, 2023; Published: March 08, 2023



Currently, in cancer or lung-cancer patients, immune checkpoint inhibitors (ICIs), such as anti-CTLA-4, anti-programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1) antibodies, etc. are widely prescribed as single agent or in combination with other anticancer- treatment modalities [1]. Due to immune-associated adverse events (iaAEs), these ICIs can facilitate antitumor effects, such as interstitial pneumonitis, endocrine-gland-disorders-associated abnormal hormone secretion [2] that can be caused and aggravated by mRNA-based-COVID-19 vaccines (Figure 1) [1,3].

Attapon Cheepsattayakorn., et al. “Immunogenicity and Safety of mRNA-COVID-19 Vaccines in Immune-Checkpoint-Inhibitor-Receiving-Lung- Cancer Patients”. EC Microbiology  19.3 (2023): 17-18.